Evidence map›Paper›PMID 41535271›Full record

Trial reportNature communications2026

Cholesterol-lowering effects of oats induced by microbially produced phenolic metabolites in metabolic syndrome: a randomized controlled trial.

Linda Klümpen, Aakash Mantri, Maren Philipps, Waldemar Seel, Laura Schlautmann, Mohamed H Yaghmour, Verena Wiemann, Birgit Stoffel-Wagner, Martin Coenen, Leonie Weinhold and 6 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Linda KlümpenInstitute of Nutrition and Food Science, Nutrition and Microbiota, University of Bonn, Bonn, Germany.
Aakash MantriInstitute of Nutrition and Food Science, Nutrition and Microbiota, University of Bonn, Bonn, Germany.ORCID http://orcid.org/0000-0001-6763-5674
Maren PhilippsLife and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany.ORCID http://orcid.org/0000-0001-5456-6104
Waldemar SeelInstitute of Nutrition and Food Science, Nutrition and Microbiota, University of Bonn, Bonn, Germany.
Laura SchlautmannLife and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany.
Mohamed H YaghmourLife and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany.ORCID http://orcid.org/0000-0003-4273-710X
Verena WiemannInstitute for Pharmaceutical Microbiology, University Hospital Bonn, University of Bonn, Bonn, Germany.
Birgit Stoffel-WagnerInstitute of Clinical Chemistry and Clinical Pharmacology, Central Laboratory, University Hospital Bonn, Bonn, Germany.
Martin CoenenInstitute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.ORCID http://orcid.org/0000-0003-0439-4409
Leonie WeinholdInstitute of Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany.
Jan HasenauerLife and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany.ORCID http://orcid.org/0000-0002-4935-3312
Thomas FließwasserInstitute for Pharmaceutical Microbiology, University Hospital Bonn, University of Bonn, Bonn, Germany.ORCID http://orcid.org/0009-0000-7413-6427
Sven BurgdorfLife and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany.ORCID http://orcid.org/0000-0001-6149-9851
Christoph ThieleLife and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany.ORCID http://orcid.org/0000-0001-5161-2558
Peter StehleInstitute of Nutrition and Food Science, Nutritional Physiology, University of Bonn, Bonn, Germany.
Marie-Christine SimonInstitute of Nutrition and Food Science, Nutrition and Microbiota, University of Bonn, Bonn, Germany. mcsimon@uni-bonn.de.ORCID http://orcid.org/0000-0001-6625-1265

Funding

Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) 01EA1707Deutsche Forschungsgemeinschaft (German Research Foundation) 432325352 - SFB 1454Deutsche Forschungsgemeinschaft (German Research Foundation) 432325352 - SFB 1454, EXC 2151-390873048
6 · The paper itself

Abstract

Oats have various positive effects on human health, but the underlying mechanisms are not fully understood. To identify oat-microbiome-host interactions contributing to metabolic improvements, we conducted two randomized controlled dietary interventions in parallel-design in individuals with metabolic syndrome, comparing a short-term, high-dose and a six-week, moderate oat intake with respective controls (DRKS00022169). Both oat diets lead to an increase in plasma ferulic acid (0.64 [0.26, 1.02], P = 0.002; 0.55 [0.21, 0.89], P = 0.003), while the high-dose oat-diet also increased dihydroferulic acid (1.23 [0.44, 2.01], P = 0.003). Here we show that microbial phenolic metabolites are driving factors for the cholesterol-lowering effect of oats, which might be of relevance since short-term, high-dose oat-diet is a suitable approach to alleviate obesity-related lipid disorders.

Indexed as

AvenaCholesterolMetabolic SyndromePhenolsAdultCoumaric AcidsFemaleGastrointestinal MicrobiomeHumansMaleMiddle AgedCholesterolCoumaric Acidsferulic acidPhenols

Identifiers

PMID41535271
PMCPMC12808737

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.